We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Laekna

News List

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase prnasia
December 27, 2021
Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the "Emerging Company Showcase" that was held earlier this month in New York.
Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China prnasia
July 06, 2021
Innovent and Laekna today jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent's PD-1 inhibitor sintilimab and Laekna's pan-AKT kinase inhibitor afuresertib.
China-based Biotech Laekna Acquires Global Rights to Develop and Commercialize anti-PD-L1 Antibody oncozine
March 30, 2020
Laekna will receive exclusive global rights to FAZ053, an investigational anti-PD-L1 antibody being developed by Novartis for the treatment of patients with advanced forms of cancer.